Australia's most trusted
source of pharma news
Thursday, 02 July 2026
Posted 2 July 2026 PM
The European Commission has opened a formal antitrust investigation into claims that Sanofi disparaged CSL’s flu vaccine Fluad.
Sanofi allegedly ran a misleading communication campaign that portrayed Fluad as inferior to Sanofi’s Efluelda (branded as Fluzone High-Dose in Australia), contravening national vaccination recommendations in several EU member states.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.